Diabetes Care, Vol 10, Issue 4 432-440, Copyright © 1987 by American Diabetes Association

ARTICLES

Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy

PJ Dyck, W Bushek, EM Spring, JL Karnes, WJ Litchy, PC O'Brien and FJ Service

Increasingly more tests are being used to detect and characterize diabetic polyneuropathy, but their value in setting minimal criteria for the diagnosis of neuropathy and for staging severity remains inadequately studied. In 180 diabetics, we compared the percentage of patients with test abnormalities and associations among test results, evaluating neuropathic symptoms [neuropathy symptom score (NSS) and neuropathy scale of neuropathy symptom profile (NNSP)], deficits [neurologic disability score (NDS) and vibratory (VDT) and cooling (CDT) detection thresholds], or nerve dysfunction [nerve conduction (NC)]. The percentage of patients that were abnormal varied considerably depending on criteria for abnormality and the tests used. Abnormality (greater than or equal to 3 SD of 1 or more parameters) of NC of one or more of four nerves occurred in 80%, of two or more in 69%, of three or more in 46%, and of four in 21%. Similarly, for other tests, the rate of abnormality decreased with use of increasingly stringent criteria. Setting the criteria for abnormal NC at abnormality of two or more nerves, NSS at greater than or equal to 1, NDS at greater than 6, NNSP at greater than or equal to 97.5th percentile, and at greater than or equal to 95th percentile for the other tests, NC was abnormal in 69%, NSS in 54%, NDS in 48%, NNSP in 47%, VDT in 44%, and CDT in 35%. Abnormality of any two or more of the six tests evaluated occurred in 64% of patients.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Quattrini, M. Jeziorska, A. J.M. Boulton, and R. A. Malik Reduced Vascular Endothelial Growth Factor Expression and Intra-Epidermal Nerve Fiber Loss in Human Diabetic Neuropathy Diabetes Care, January 1, 2008; 31(1): 140 - 145. [Abstract] [Full Text] [PDF]

				S. Mehra, M. Tavakoli, P. A. Kallinikos, N. Efron, A. J.M. Boulton, T. Augustine, and R. A. Malik Corneal Confocal Microscopy Detects Early Nerve Regeneration After Pancreas Transplantation in Patients With Type 1 Diabetes Diabetes Care, October 1, 2007; 30(10): 2608 - 2612. [Abstract] [Full Text] [PDF]

				C. M. Casellini, P. M. Barlow, A. L. Rice, M. Casey, K. Simmons, G. Pittenger, E. J. Bastyr III, A. M. Wolka, and A. I. Vinik A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-{beta} Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy Diabetes Care, April 1, 2007; 30(4): 896 - 902. [Abstract] [Full Text] [PDF]

				C. Quattrini, N. D. Harris, R. A. Malik, and S. Tesfaye Impaired Skin Microvascular Reactivity in Painful Diabetic Neuropathy Diabetes Care, March 1, 2007; 30(3): 655 - 659. [Abstract] [Full Text] [PDF]

				L. G. Goransson, A. Herigstad, A. B. Tjensvoll, E. Harboe, S. I. Mellgren, and R. Omdal Peripheral Neuropathy in Primary Sjogren Syndrome: A Population-Based Study Arch Neurol, November 1, 2006; 63(11): 1612 - 1615. [Abstract] [Full Text] [PDF]

				L. G. Goransson, A. B. Tjensvoll, A. Herigstad, S. I. Mellgren, and R. Omdal Small-diameter nerve fiber neuropathy in systemic lupus erythematosus. Arch Neurol, March 1, 2006; 63(3): 401 - 404. [Abstract] [Full Text] [PDF]

				C. S. Andreassen, J. Jakobsen, and H. Andersen Muscle Weakness: A Progressive Late Complication in Diabetic Distal Symmetric Polyneuropathy Diabetes, March 1, 2006; 55(3): 806 - 812. [Abstract] [Full Text] [PDF]

				A. V. Krishnan, R. K. S. Phoon, B. A. Pussell, J. A. Charlesworth, H. Bostock, and M. C. Kiernan Altered motor nerve excitability in end-stage kidney disease Brain, September 1, 2005; 128(9): 2164 - 2174. [Abstract] [Full Text] [PDF]

				A. V. Krishnan and M. C. Kiernan Altered nerve excitability properties in established diabetic neuropathy Brain, May 1, 2005; 128(5): 1178 - 1187. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Diabetic Retinopathy and Neuropathy Diabetes Care, April 1, 2005; 28(4): 963 - 970. [Full Text] [PDF]

				S. T.M. Krishnan and G. Rayman The LDIflare: A novel test of C-fiber function demonstrates early neuropathy in type 2 diabetes Diabetes Care, December 1, 2004; 27(12): 2930 - 2935. [Abstract] [Full Text] [PDF]

				L. H. Zinman, V. Bril, and B. A. Perkins Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments Diabetes Care, July 1, 2004; 27(7): 1674 - 1679. [Abstract] [Full Text] [PDF]

				S. T.M. Krishnan, N. R. Baker, A. L. Carrington, and G. Rayman Comparative Roles of Microvascular and Nerve Function in Foot Ulceration in Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1343 - 1348. [Abstract] [Full Text] [PDF]

				J-P Lefaucheur and A Creange Neurophysiological testing correlates with clinical examination according to fibre type involvement and severity in sensory neuropathy J. Neurol. Neurosurg. Psychiatry, March 1, 2004; 75(3): 417 - 422. [Abstract] [Full Text] [PDF]

				N. I. Spielholz, P. J. Dyck, P. C. O'Brien, M. E. Shy, and E. M. Frohman Quantitative sensory testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, December 9, 2003; 61(11): 1628 - 1630. [Full Text] [PDF]

				A. Caselli, J. Rich, T. Hanane, L. Uccioli, and A. Veves Role of C-nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes Neurology, January 28, 2003; 60(2): 297 - 300. [Abstract] [Full Text] [PDF]

				D. Strumberg, S. Brugge, M. W. Korn, S. Koeppen, J. Ranft, G. Scheiber, C. Reiners, C. Mockel, S. Seeber, and M. E. Scheulen Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer Ann. Onc., February 20, 2002; 13(2): 229 - 236. [Abstract] [Full Text] [PDF]

				D. Simovic, J. M. Isner, A. H. Ropper, A. Pieczek, and D. H. Weinberg Improvement in Chronic Ischemic Neuropathy After Intramuscular phVEGF165 Gene Transfer in Patients With Critical Limb Ischemia Arch Neurol, May 1, 2001; 58(5): 761 - 768. [Abstract] [Full Text] [PDF]

				L. Vahdat, K. Papadopoulos, D. Lange, S. Leuin, E. Kaufman, D. Donovan, D. Frederick, E. Bagiella, A. Tiersten, G. Nichols, et al. Reduction of Paclitaxel-induced Peripheral Neuropathy with Glutamine Clin. Cancer Res., May 1, 2001; 7(5): 1192 - 1197. [Abstract] [Full Text]

				S. C. Apfel, S. Schwartz, B. T. Adornato, R. Freeman, V. Biton, M. Rendell, A. Vinik, M. Giuliani, J. C. Stevens, R. Barbano, et al. Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial JAMA, November 1, 2000; 284(17): 2215 - 2221. [Abstract] [Full Text] [PDF]

				D. R. Cornblath, V. Chaudhry, K. Carter, D. Lee, M. Seysedadr, M. Miernicki, and T. Joh Total neuropathy score: Validation and reliability study Neurology, November 1, 1999; 53(8): 1660 - 1660. [Abstract] [Full Text]

				G. I. Wolfe, N. S. Baker, A. A. Amato, C. E. Jackson, S. P. Nations, D. S. Saperstein, C. H. Cha, J. S. Katz, W. W. Bryan, and R. J. Barohn Chronic Cryptogenic Sensory Polyneuropathy: Clinical and Laboratory Characteristics Arch Neurol, May 1, 1999; 56(5): 540 - 547. [Abstract] [Full Text] [PDF]

				J. E. Riggs, S. C. Apfel, W. J. Litchy, J. A. Kessler, C. Sanders, B. T. Adornato, and C. A. Rask Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy Neurology, April 1, 1999; 52(7): 1517 - 1517. [Full Text]